

Product datasheet for TL316755V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Thymine DNA glycosylase (TDG) Human shRNA Lentiviral Particle (Locus ID 6996)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Thymine DNA glycosylase (TDG) Human shRNA Lentiviral Particle (Locus ID 6996)

Locus ID: 6996

Synonyms: E130317C12Rik; JZA-3; Jza1; OTTMUSP00000028912; OTTMUSP00000028913; thymine DNA

glycosylase

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: TDG - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001008411, NM 003211, NM 003211.1, NM 003211.2, NM 003211.3, NM 003211.4,

BC037557, BC037557.1, BC001307, BC010945, BC019925, BC071714, BC104477,

NM 001363612

UniProt ID: Q13569

Summary: The protein encoded by this gene belongs to the TDG/mug DNA glycosylase family. Thymine-

DNA glycosylase (TDG) removes thymine moieties from G/T mismatches by hydrolyzing the carbon-nitrogen bond between the sugar-phosphate backbone of DNA and the mispaired

thymine. With lower activity, this enzyme also removes thymine from C/T and T/T

mispairings. TDG can also remove uracil and 5-bromouracil from mispairings with guanine. This enzyme plays a central role in cellular defense against genetic mutation caused by the

spontaneous deamination of 5-methylcytosine and cytosine. This gene may have a pseudogene in the p arm of chromosome 12. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).